|
|
Article: Seattle Genetics Highlights Pipeline Progress and Reports Third Quarter 2009 Financial Results.(Financial report)
- Article from:
- Blood Weekly
- Article date:
- November 5, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Seattle Genetics, Inc. (Nasdaq:SGEN) reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress (see also Seattle Genetics, Inc.).
"We achieved several significant milestones during the third quarter, including completing enrollment in the pivotal clinical trial of brentuximab vedotin, our lead antibody-drug conjugate (ADC) for Hodgkin lymphoma," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "We expect data from the pivotal trial in the second half of 2010, and are continuing to position the program for a planned U.S. product ...